Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][4] - The company will participate in a fireside chat and KOL webinar on October 10, 2025, featuring discussions on schizophrenia treatment and clinical data for its lead drug candidate, brilaroxazine [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4]